Pulmozyme and Multi-therapy Approach
Pulmozyme is often a component of a Multi-therapy Approach in the management of cystic fibrosis 15-19
Every prescribed therapy plays an important role in managing the destructive cycle of cystic fibrosis by targeting different disease mechanisms 15-19
A multi-therapy approach targets different disease mechanisms
NOTE: In several pivotal phase 3 trials assessing the efficacy and safety of CFTR modulators, patients continued to receive their Pulmozyme treatment15-19
Controlling mucus is an essential component in the management of cystic fibrosis 7
3. Harms HK et al. Dnase International Study Group. Multicenter, open-label study of recombinant human Dnase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998; 23(3): 155-161;
4. King, M. Mucolytics and mucus clearance. In Rubin BK, van der Sxhans CP, eds. Therapy for Mucus-Clearance Disorders. New Yoirk, NY: Marcel Dekker Inc, 2004:201-224;
5. Chmiel, JF, Kanstan MW. Anti-inflammatory medication for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005; 4(4):255-273;
6. Puchelle E et al. Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration. 1995; 62(suppl 1) 2-12;
7. Lyczak, JB et al. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2—2; 15(2):194-222.
15. Orkambi summary of product characteristics. Vertex Pharmaceuticals (Europe) Ltd.
16. Wainwright CE et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231.
17. Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
18. Davies JC. Et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-1225.
19. Kalydeco summary of product characteristics. Vertex Pharmaceuticals (Europe) Ltd.
20. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2015. https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report. Accessed April 3, 2017.
21. Clancy JP. Ongoing research into CFTR modulation. Adv Stud Med. 2010;10(1):14-18.
22. Bennet, WD et al. Hydrator therapies for chronic bronchitis: lessons from cystic fibrosis. Ann Am Thorac Soc. 2016;13(2):S186-S190.
Video: Cystic Fibrosis Foundation. Treatment and Therapies. https://www.cff.org/Life-with-CF/Treatments-and-Therapies/
Learn more about cystic fibrosis at managingcysticfibrosis.com
This website contains information which can target a wide range of audiences and could contain details and information not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
M-XX-00000028 | Date of preparation: October 2019
